PETS

PetMed Express, Inc. PETS used its fourth-quarter fiscal 2026 earnings call to emphasize stabilization rather than a clean recovery. Management said fiscal 2026 was a reset year marked by operational cleanup, cost actions and technology upgrades aimed at rebuilding the business foundation. The call mattered because PetMed paired that turnaround message with signs of slower sales erosion in the second half, modest sequential revenue improvement in Q4 and a decision to remain independent after reviewing acquisition proposals. Leslie Campbell, executive chairman, interim chief executive officer and president, described fiscal 2026 as a pivotal year in which the company worked through financial, operational and cultural issues. She said the first half remained difficult, but the second half showed progress in stabilizing the core business and preparing for longer-term improvement. Campbell pointed to slowing year-over-year sales declines in both the fiscal third quarter and fourth quarter. She also highlighted a sequential increase in fourth-quarter net sales, which she said was the company’s first fourth-quarter sequential gain since fiscal 2024. That framing set the tone for the call. Rather than presenting a broad-based rebound, management focused on early signs that internal actions are beginning to show up in sales trends and customer activity. Campbell said the second half brought “green shoots” in prescription medication sales, prescription and nonprescription food sales and autoship sign-ups. Those were important markers because prescription medication remains the company’s largest pressure point and the main driver of the year’s revenue decline. Douglas Krulik, chief accounting officer and interim principal financial officer, said fourth-quarter net sales were $42.8 million, down 15.6% from a year earlier. Net sales surpassed the Zacks Consensus Estimate of $42 million by 1.27%. The reported loss of 19 cents per share was wider than the Zacks Consensus Estimate of a loss of 18 cents, delivering a negative surprise of 5.56%. PetMed Express, Inc. price-consensus-eps-surprise-chart | PetMed Express, Inc. Quote Krulik added that the fiscal fourth quarter still improved sequentially from the third quarter, helped by prescription medication and autoship trends. That gave management a tangible point of support for its argument that the back-half strategy is st...

This article first appeared on GuruFocus. Release Date: June 02, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. PetMed Express Inc (NASDAQ:PETS) made significant financial, operational, and cultural improvements in fiscal year 2026, aiming for sustainable long-term results. The company regained critical regulatory compliance and improved internal controls, remediating three previously disclosed material weaknesses. There was a sequential quarterly increase in fourth quarter net sales, marking the first Q4 sequential increase since fiscal year 2024. Cost reduction efforts led to exiting underperforming vendor relationships, yielding approximately $6.1 million in annualized savings. PetMed Express Inc (NASDAQ:PETS) completed several important technology and infrastructure initiatives, including a new ERP system and fraud prevention system, enhancing operational efficiency. Net sales for the full fiscal year 2026 were down 21.1%, with a 15.6% decline in the fourth quarter compared to the prior year. The company reported a net loss of $57.3 million for the full fiscal year, significantly higher than the $6.3 million loss in the prior year. Several significant non-recurring accounting entries, including a $26.7 million non-cash goodwill impairment and a $2.1 million wholesale inventory write-down, impacted financial results. PetMed Express Inc (NASDAQ:PETS) incurred $4.5 million in non-recurring legal, professional, and executive severance costs related to a whistleblower investigation. Despite improvements, the company faced challenges with a decline in prescription medication sales, impacting overall revenue. Warning! GuruFocus has detected 3 Warning Signs with PETS. Is PETS fairly valued? Test your thesis with our free DCF calculator. Q: Can you provide more details on the financial improvements made in the second half of fiscal year 2026? A: Leslie Campbell, Interim CEO and President, explained that PetMed Express made significant progress in stabilizing its core business and strengthening its foundation for future value creation. This included regaining critical regulatory compliance, improving internal controls, and achieving a sequential quarterly increase in Q4 net sales, the first since fiscal year 2024. Q: What were the main factors contributing to the decline in net sales for fiscal year 2026?...

Image source: The Motley Fool. Tuesday, June 2, 2026, at 4:30 p.m. ET Chairman of the Board, Interim CEO, and President — Leslie C. G. Campbell Chief Financial Officer — Doug Krulik Leslie C. G. Campbell, PetMed's Chairman of the Board and Interim CEO and President. Leslie C. G. Campbell: Thank you, Reed, and welcome to everyone joining our call this afternoon. Following my remarks, Doug will provide a detailed overview of our financial results. Fiscal year 26 was a pivotal year for PetMed Express. During which we made significant financial, operational, and cultural improvements that are aimed at putting the company back on track for sustainable long term results. While our full year results reflect the challenges we faced particularly in the first half of the year, I am pleased to report that we made substantial progress in the second half of the year in stabilizing our core business and strengthening our foundation for future value creation. In the second half of the year, we also regained critical regulatory compliance. With the filing of our Form 10-K for fiscal year 25 in October and the completion of our fiscal year 26 Q1 and Q2 quarterly filings in December. In December, we also announced the change in our external auditor firm to Baker Tilly US LLP. 12/31/2025. And we then successfully held our annual shareholder meeting for fiscal year 25 in January. You will see in today's 10 k filing we also made meaningful progress in improving our internal controls. Fully remediating 3 previously disclosed weaknesses. Tone at the top, complex accounting issues, and income taxes. Although Doug will speak to our financial results in a moment, I would like to provide a little bit of additional detail now. Our net sales for the full fiscal year 2026 were down 21.1%. But we saw a slowing of year over year revenue decline in Q3 and again in Q4, with Q4 being down 15.6% compared to the prior year, or 17.8% adjusted for the settlement of our New York State sales tax liability. We also began to see green shoots in the second half of the year in important areas like prescription medication sales, prescription and nonprescription food sales, and auto ship sign ups. And we were pleased to deliver a sequential quarterly increase in fourth quarter net sales, our first Q4 sequential quarterly increase since fiscal year 24. Demonstrating some positive momentum. These improveme...

DELRAY BEACH, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its fourth quarter and fiscal year ended March 31, 2026. Fourth Quarter Fiscal 2026 Financial Highlights Compared to Prior Year Period Net sales of $42.8 million compared to $50.8 million in the prior year period, a decrease of 15.6%, primarily driven by a decline in prescription medication sales. Net loss of $4.1 million, or $(0.19) per diluted share, compared to a net loss of $11.6 million, or $(0.56) per diluted share, for the prior year period. The decrease in the net loss can be attributed to lower general and administrative expenses, the absence of the prior-year trade name impairment charge, higher interest income, and a lower provision for income taxes, driven by the Company establishing a full valuation allowance against its net deferred tax asset in the prior year period. These favorable factors were partially offset by lower gross profit resulting from decreased net sales. Adjusted EBITDA1 was $(2.8) million compared to $(1.9) million in the prior year period. Full Year Fiscal 2026 Financial Highlights Compared to Prior Year Net sales of $179.0 million compared to $227.0 million in the prior year, a decrease of 21.1%, primarily driven by a decline in prescription medication sales. Net loss of $57.3 million, or $(2.74) per diluted share, compared to a net loss of $6.3 million, or $(0.30) per diluted share in the prior year. The increase to net loss was primarily driven by a goodwill impairment charge of $26.7 million recorded in the first quarter of fiscal 2026, an increase in stock-based compensation expense, driven by the non-recurrence of an $8.7 million one-time non-cash stock compensation reversal associated with executive departures in the prior year, an increase in professional fees and executive severance costs, of which $4.5 million were one-time charges related to the whistleblower investigation, and lower gross profit resulting from decreased net sales. These factors were partially offset by a lower provision for income taxes, driven by the Company establishing a full valuation allowance against its net deferred tax asset in the prior year. Adjusted EBITDA was $(15.4) million compared to $0.7 million for the prior year. “We are pleased to report a modest sequential...

DELRAY BEACH, Fla. (AP) — DELRAY BEACH, Fla. (AP) — PetMed Express Inc. (PETS) on Tuesday reported a loss of $4.1 million in its fiscal fourth quarter. On a per-share basis, the Delray Beach, Florida-based company said it had a loss of 19 cents. The pet pharmacy company posted revenue of $42.8 million in the period. For the year, the company reported a loss of $57.3 million, or $2.74 per share. Revenue was reported as $179 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PETS at https://www.zacks.com/ap/PETS

PetMed Express (PETS) reported a fiscal Q4 loss late Tuesday of $0.19 per diluted share, narrowing f

DELRAY BEACH, Fla., May 29, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the fourth quarter and fiscal year ended March 31, 2026, on Tuesday, June 2, 2026 after market close. The Company will host a conference call and webcast to discuss these results at 4:30pm Eastern Time on the same day. Date: Tuesday, June 2, 2026Time: 4:30pm Eastern Time (1:30pm Pacific Time)U.S. dial-in number: 877-407-0789International number: 201-689-8562Webcast: 4Q Earnings Webcast A telephonic replay of the conference call will also be available after 7:30 PM Eastern Time on the same day through June 16, 2026. Toll-free replay number: 844-512-2921 International replay number: 412-317-6671 Replay passcode: 13760873 About PetMed Express, Inc. Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PETS family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com. Investor Contact:ICR, LLCReed Anderson(646) [email protected]

DELRAY BEACH, Fla. (AP) — DELRAY BEACH, Fla. (AP) — PetMed Express Inc. (PETS) on Friday reported a loss of $34.2 million in its fiscal first quarter. The Delray Beach, Florida-based company said it had a loss of $1.65 per share. Losses, adjusted for asset impairment costs, were 34 cents per share. The pet pharmacy company posted revenue of $51.2 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PETS at https://www.zacks.com/ap/PETS

DELRAY BEACH, Fla. (AP) — DELRAY BEACH, Fla. (AP) — PetMed Express Inc. (PETS) on Friday reported a loss of $8.5 million in its fiscal second quarter. On a per-share basis, the Delray Beach, Florida-based company said it had a loss of 41 cents. The pet pharmacy company posted revenue of $44.4 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PETS at https://www.zacks.com/ap/PETS

DELRAY BEACH, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company”), today announced preliminary second quarter fiscal year 2026 results and filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission. The Company is unable to file its Form 10-Q for the quarter ended September 30, 2025 within the prescribed time period without unreasonable effort or expense. Preliminary Second Quarter Net Sales: For the fiscal second quarter ended September 30, 2025, net sales are estimated to range from $43.4 million to $44.5 million compared to $58.0 million (as restated) in the prior year period. For the six months ended September 30, 2025, net sales are estimated to range from $94.5 million to $95.6 million compared to $124.3 million (as restated) in the prior year period. The Company is unable at this time to provide a reasonable estimate of operating income or net income for the three- and six-month periods ended September 30, 2025, due to an ongoing analysis of the timing and amount of an anticipated goodwill impairment charge that was previously discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025, that was filed on October 14, 2025 (see Note 19 to the Consolidated Financial Statements included in said Form 10-K). The Company had $36.1 million of cash and no debt as of September 30, 2025. The financial information provided herein is estimated and unaudited, and the Company’s actual results may differ from these results due to final adjustments and developments that may arise or information that may become available between now and the time the Company’s financial statements are finalized and included in the Company’s Form 10-Q for the quarter ended September 30, 2025. Receipt of Notice of Non-Compliance from Nasdaq: On November 12, 2025, the Company received an expected notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 (the “Q2 10-Q”), in addition to its continued delinquency in filing its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the “Q1 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)...

DELRAY BEACH, Fla., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today filed with the Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the fiscal year ended March 31, 2025. Fiscal 2025 Financial Highlights Net sales of $227.0 million for fiscal 2025, below the preliminary estimated range of $231.6 million to $233.6 million, primarily due to the previously announced restatement of promotional sales reimbursements from revenues to cost of sales, which had no impact on net income Net loss of $6.3 million, more than the previously announced preliminary estimated range of $4.5 million to $5.0 million, primarily due to the previously announced $1.2 million non-cash impairment charge for intangible assets Cash of $54.7 million as of March 31, 2025, and no debt “We greatly appreciate the patience of our shareholders over the past several months,” said Board Chair and Interim CEO Leslie C. G. Campbell. “With our Form 10-K for fiscal 2025 now filed and actions taken to enhance our internal processes, we can now fully dedicate our efforts to operational execution and building a platform for long-term value creation. Most importantly we will continue to deliver to our customers the care they trust, which has been our legacy as a pioneer in the digital pharmacy industry for nearly 30 years. We now plan to file, as soon as practicable, our Quarterly Report on Form 10-Q for the first quarter ended June 30, 2025, followed by our earnings results and corresponding filings for the second quarter ended September 30, 2025, and thereby resume the normal quarterly reporting schedule. While we are unable at this time to determine exact dates for our Q1 and Q2 filings with the SEC or the related earnings announcements, we expect to resume our normal cadence of quarterly earnings calls promptly once our SEC filings are current.” About PetMed Express, Inc. Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness and the veterinarians who serve them. Through its PETS family of brands, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceutica...